Dilafor
Dilafor AB is a Swedish, privately held drug development company developing tafoxiparin, a proprietary heparan sulfate mimetic in Phase 3 development for priming of labor in term pregnant women, monetizing through regional licensing partnerships (Exeltis, Lee's Pharmaceutical) and Opocrin manufacturing.
- Company typePrivate
- Founded2003
- HeadquartersSolna, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dilafor does
Dilafor AB is a privately held Swedish drug development company founded in 2003 and headquartered at the Karolinska Institutet Science Park in Solna, Sweden. It is a single-asset, late-stage clinical company developing tafoxiparin, a proprietary heparan sulfate mimetic designed to initiate cervical ripening and myometrial remodeling to enable spontaneous onset of labor in term pregnant women, particularly first-time mothers planned for labor induction. The product is administered subcutaneously (with a planned daily autoinjector for home use) and has been evaluated in clinical studies on more than 650 pregnant women, with Phase IIb data showing 59% spontaneous onset or ripe cervix versus 39% on placebo and statistically significant cervical ripening (p<0.009). Preclinical data indicate tafoxiparin does not cross the placenta.
Dilafor does not sell a commercial product. Its business model is asset-light and licensing-driven: it captures upfront payments, development and sales milestones, and royalties from regional pharmaceutical partners who fund and execute late-stage clinical development and commercialization. The January 2026 binding term sheet with Exeltis (part of Insud Pharma) grants an exclusive semi-global license excluding China and Japan, with Exeltis funding pivotal Phase 3 trials and commercialization in exchange for milestones and stepped royalties up to double-digits. Lee's Pharmaceutical holds the China/Hong Kong/Macau/Taiwan rights (since 2014), and Opocrin S.p.A. is the commercial manufacturing partner for Europe, the US, CIS and Japan and also an equity holder. The company is owned primarily by KDev Investments AB (jointly held by KDventures AB, formerly Karolinska Development, and Rosetta Capital), alongside Östersjöstiftelsen and Praktikerinvest PE AB.
The asset is supported by substance and method-of-use patent protection, including a US patent granted October 2025 extending exclusivity for priming of labor until at least May 2043, alongside completed regulatory alignment with the FDA and European authorities (including a December 2024 SNSA with five EU national agencies) on Phase 3 study design. With no approved product, revenue is limited to licensing milestones; the addressable market is large, with US market analyses indicating a drug that induces cervical ripening could exceed USD 1 billion in annual US sales, and 30–50% of term pregnant women globally experiencing planned labor initiation.
Dilafor firmographics
Firmographics- Name
- Dilafor
- Legal name
- Dilafor AB
- Website
- https://dilafor.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Dilafor AB is a Swedish, privately held drug development company developing tafoxiparin, a proprietary heparan sulfate mimetic in Phase 3 development for priming of labor in term pregnant women, monetizing through regional licensing partnerships (Exeltis, Lee's Pharmaceutical) and Opocrin manufacturing.
- Ownership category
- akta.pro rank
Dilafor industry classification
Industry- Product category
- Obstetric Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Dilafor is headquartered
LocationHeadquarters
- HQ city
- Solna
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Dilafor business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Licensing and Royalty Revenue: Dilafor generates revenue through licensing agreements with pharmaceutical partners. The Exeltis agreement includes upfront payments, development-based milestones, sales-based milestone payments, and up to double-digit royalties on net sales. The Lee's Pharmaceutical agreement includes upfront payments, development and sales milestones, plus royalties on sales in licensed territories.
- Milestone Payments: Revenue from development and commercial milestone payments tied to clinical progress, regulatory approvals, and sales performance under partnership agreements.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Dilafor product offering
Product offeringCore offering
Dilafor AB develops tafoxiparin, a proprietary heparan sulfate mimetic drug candidate designed for priming of labor in term pregnant women. The drug is administered as a daily subcutaneous injection or autoinjector to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. The company has completed Phase IIb clinical trials on more than 650 pregnant women and is preparing for Phase 3 trials following regulatory alignment with the FDA and European authorities.
Product overview
Dilafor is a pharmaceutical development company with a single lead product - tafoxiparin, a proprietary heparan sulfate mimetic. The company focuses exclusively on developing this drug candidate for obstetrical indications, specifically priming of labor. Tafoxiparin is the company's sole product in advanced clinical development (Phase 3 ready), designed to enable cervical ripening and myometrial remodeling for spontaneous labor onset in term pregnant women.
Differentiator
Problem solved
Functional benefit
Products and services
- Tafoxiparin Proprietary heparan sulfate mimetic drug candidate in late-stage clinical development (Phase 3 ready) for priming of labor. It is administered as a daily subcutaneous injection or autoinjector to term pregnant women (particularly first-time mothers with unripe cervix planned for labor induction) to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. Clinical studies on 650+ pregnant women showed 59% experienced spontaneous onset of labor or ripe cervix versus 39% placebo, with safety profile supporting potential home-based self-administration.
Quantifiable outcome
- 59% of tafoxiparin-treated women experienced spontaneous onset of labor or reached a ripe cervix compared to 39% in placebo group
- +4 more outcomes
Companies that use Dilafor
Customer profileSegments2 records
Ideal customer profiles2 records
Dilafor technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Dilafor partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- ExeltiscoreDilafor signed a binding term sheet with Exeltis, a global Women's Health company and part of Insud Pharma, for an exclusive semi-global license (excluding China and Japan) to develop and commercialize tafoxiparin for priming of labor. Exeltis will fund pivotal clinical trials, development, and commercialization. The deal includes milestone payments primarily linked to commercial performance and stepped royalties increasing based on net sales, with potential for up to double-digit royalties.
- Liverpool UniversityminorResearch collaboration with Liverpool University to study the potential inhibitory effect of tafoxiparin on SARS-CoV-2. Researchers provided evidence that heparin binds to the spike protein on SARS-CoV-2, and non-coagulant heparan sulfate mimetics like tafoxiparin may exhibit similar qualities. Dilafor provided tafoxiparin, data, and in-house knowledge.
- Opocrin S.p.AcoreCommercial manufacturing and partnership agreement with Opocrin for manufacturing of the active ingredient tafoxiparin. Opocrin appointed as main commercial manufacturing partner for European, US, CIS, and Japanese markets. Opocrin also made an investment in Dilafor as part of the agreement.
- Lee's Pharmaceutical Holdings LtdcoreLicense and partnership agreement granting Lee's Pharmaceutical rights to manufacture, develop, and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau, and Taiwan. Lee's will conduct and finance Phase II and Phase III trials in China. Dilafor receives upfront payment, development and sales milestones, plus royalties on sales.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Dilafor competitors and assessment
Company assessmentDirect peers
- ObsEva SA: Clinical-stage biopharmaceutical company focused on women's health and reproductive medicine, including obstetric indications. Directly comparable as a small-cap, late-stage clinical developer addressing underserved areas of obstetrics with a similar licensing and partnership-driven business model.
- Dare Bioscience: Clinical-stage biopharmaceutical company focused on women's health with multiple late-stage programs. Comparable as a small, women-focused clinical developer pursuing underserved obstetric and gynecologic indications with similar licensing and partnership GTM.
Broad incumbents
- Ferring Pharmaceuticals: Large privately-held reproductive health and obstetrics company that markets Cervidil (dinoprostone) and other labor induction products. Directly comparable as a key player in the labor induction space whose established products represent the standard-of-care Dilafor's tafoxiparin aims to disrupt.
- TherapeuticsMD: Women's health-focused pharmaceutical company commercializing products across contraception, hormone therapy, and obstetrics. Comparable as a publicly-traded, women's health-focused pharma peer whose specialty commercial model and target prescribers overlap with Dilafor's obstetric market.
- Organon & Co. Global women's health company spun out from Merck, with established franchises in contraception, fertility, and obstetrics. Comparable as a broad incumbent women's health company whose commercial footprint and physician relationships represent the channel Dilafor's eventual launch would target.
- AMAG Pharmaceuticals (Covis Pharma): Women's health-focused pharmaceutical company (now part of Covis) with obstetric products such as Makena. Comparable as a women's health specialty player with established commercial infrastructure in obstetrics that competes for the same physician audience as a future tafoxiparin launch.
- Hologic: Diversified women's health company with significant presence in diagnostics, surgical, and obstetric markets. Comparable as a broad women's health incumbent whose existing OB/GYN commercial relationships and customer overlap make it a relevant strategic benchmark.
- CooperSurgical: Major women's health and fertility medical device and pharmaceutical company, including products in assisted reproduction and obstetrics. Comparable as a broad incumbent serving the same maternal-fetal health customer base that tafoxiparin would target.
Emerging players
- Evofem Biosciences: Women's health commercial-stage company focused on reproductive health products including hormone-free contraception. Comparable as a smaller, publicly-traded women's health specialist competing in overlapping OB/GYN prescribing channels with novel, underserved-mechanism products.
Others
- Insud Pharma (Exeltis parent): Spanish multinational pharmaceutical group operating in 40+ countries; parent of Exeltis, Dilafor's semi-global licensee for tafoxiparin. Included as an ecosystem participant and the commercial vehicle through which Dilafor would realize non-Asia ex-Japan royalties.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Dilafor social profiles
Digital presenceDilafor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dilafor leadership team
Management profileNumber of profiles
Profiles14 records
Dilafor funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dilafor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dilafor
What does Dilafor do?
Dilafor AB develops tafoxiparin, a proprietary heparan sulfate mimetic drug candidate designed for priming of labor in term pregnant women. The drug is administered as a daily subcutaneous injection or autoinjector to facilitate cervical ripening and myometrial remodeling, enabling spontaneous onset of labor. The company has completed Phase IIb clinical trials on more than 650 pregnant women and is preparing for Phase 3 trials following regulatory alignment with the FDA and European authorities.
Is Dilafor a public or private company?
Dilafor is a private company. It is classified as venture growth investor backed and is currently operating.
When was Dilafor founded?
Dilafor was founded in 2003. It employs 11 to 50 people.
Where is Dilafor based?
Dilafor is headquartered in Solna, Sweden, in the Europe region.
How does Dilafor make money?
Two revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are milestone Payments.
Who are Dilafor's main competitors?
Direct peers on record are ObsEva SA and Dare Bioscience. Broad incumbents are Ferring Pharmaceuticals, TherapeuticsMD, Organon & Co., AMAG Pharmaceuticals (Covis Pharma), Hologic and CooperSurgical. Evofem Biosciences is listed as an emerging player. Insud Pharma (Exeltis parent) is listed as an others.
Does Dilafor have an API?
No public API is recorded for Dilafor.
What industry is Dilafor in?
Dilafor's product category is Obstetric Pharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 325412 and its SIC code is 2834.